Effects of Metformin on Serum Insulin, AMH and on Androgen Level in Patients with PCOS

Background: Between five and ten females of reproductive age are affected by polycystic ovary syndrome (PCOS), which is the most prevalent cause of anovulation, hyperandrogenism, and infertility. Aim and objectives: To estimate the impact of metformin on the levels of anti-mullerian hormone (AMH), androgen, and serum insulin in cases with POS. Patients and methods: This investigation has been performed from January 2023 to June 2023 on 70 women randomly categorized into 2 groups: Group A(PCOS) is composed of 50 females with PCOS. Group B (the control group) was composed of 20 eumenorrheic volunteers who did not have endocrinopathies and were located at El Hussein University Hospital, Obstetrics and Gynecology Department. After the approval of the research ethics committee, patients were selected from an outpatient clinic. Results: Regarding hormonal data after metformin use, there was a statistically insignificant variance between the investigated groups according to follicle-stimulating hormone (FSH), prolactin, luteinizing hormone (LH), insulin, 17 OHP, testosterone, clinic after the research ethics committee's up testosterone, HEA-S. While there was a highly statistically significant variance between the investigated groups, according to AMH. Conclusion: Regarding hormonal data before metformin use, there was a statistically significant difference between the studied groups according to FSH, and there was a highly statistically significant variance according to LH, LH/FSH ratio, 17 OHP, insulin, testosterone, and AMH. Also, we found that regarding hormonal data after metformin use, there was statistically insignificant variance according to LH, FSH, prolactin,17 OHP, insulin, testosterone, and DHEA-S, while there was highly statistically significant variance according to AMH.